We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Metastatic Breast Cancer
Center of Excellence
Interested in receiving weekly updates about the Metastatic Breast Cancer Center of Excellence?
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Saiji Nageshwaran
Nov 29, 2019
Could also give 4x 2 weekly dose dense Paclitaxel instead of weekly. Also consider BRCA and risk reduction contralateral if not already done.
Isabel Pimentel
Nov 29, 2019
BRCA status? I would consider her for a clinical trial with cdKi in the adjuvant setting.
Stefan Todorov
Nov 29, 2019
Neoadjuvant cdk4/6 inhibitor plus aromataseinhibitor?
Carlos Calderon
Nov 29, 2019
The ovarian ablation, premature menopause may be associated with long-term health effects, including cardiovascular disease, so in this case 10 years of OFS is something to consider, maybe OFS for 5 years and continuing tamoxifen could be a good strategy, bisphosphonates as prevention of bone loss is another good recommendation. I agree with the importance of Brca status in this patient.
Olivera Ivanov
Dec 03, 2019
What about radiotherapy of the thoracic wall?
Apr 26, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Saiji Nageshwaran
Nov 29, 2019
Isabel Pimentel
Nov 29, 2019
Stefan Todorov
Nov 29, 2019
Carlos Calderon
Nov 29, 2019
Olivera Ivanov
Dec 03, 2019
Apr 26, 2024
Pending Moderator approval.